Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) m...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241311058 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846095880855224320 |
|---|---|
| author | Ming Gao Xia Zhang Huan Yan Yan Zhao Fang Yuan Decong Sun Xuejiao Yang Yanfang Ju Lijie Wang Haitao Tao Luyuan Tian Changhong Zhao Junxun Ma Yi Hu Zhefeng Liu |
| author_facet | Ming Gao Xia Zhang Huan Yan Yan Zhao Fang Yuan Decong Sun Xuejiao Yang Yanfang Ju Lijie Wang Haitao Tao Luyuan Tian Changhong Zhao Junxun Ma Yi Hu Zhefeng Liu |
| author_sort | Ming Gao |
| collection | DOAJ |
| description | Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC. Design: A single-center, single-arm, phase II study. Methods: Previously treated patients with locally advanced and metastatic NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutation genes had received at least one EGFR tyrosine kinase inhibitor and no more than two lines of chemotherapy regimen before the enrollment. The other patients had progressed on first-line chemotherapy with or without immunotherapy before the enrollment. The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by the investigator. Results: Our study encompassed 23 NSCLC patients between October 2019 and October 2022. For all patients, the confirmed ORR was 30.4%, and the disease control rate was 95.7%. The median progression-free survival (PFS) was 6.9 months (95% CI: 4.9 months–not reached). The median overall survival (OS) was not reached. 1- and 2-year OS rates were 85.6% (95% CI: 71.8%–100.0%) and 56.8% (95% CI: 37.7%–85.7%). Especially, for the 6 patients with EGFR genetic aberrations, the confirmed ORR was 33.3%, the median PFS was 10.3 months (95% CI: 1.8–18.8 months), and the median OS was 20.3 months (95% CI: 0.8–39.8 months). The most common grade 3 and above treatment-related adverse events were platelet count decreased, white blood cell count decreased, and hypertension. No unexpected adverse events were reported. Conclusion: Camrelizumab plus famitinib demonstrated encouraging clinical activity with a manageable safety profile in previously treated patients with locally advanced and metastatic NSCLC. The results warranted further validation. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR1900026641. |
| format | Article |
| id | doaj-art-a48f52d9223d48c8b9a06a9273b2c6c4 |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-a48f52d9223d48c8b9a06a9273b2c6c42025-01-02T09:03:23ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-01-011710.1177/17588359241311058Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trialMing GaoXia ZhangHuan YanYan ZhaoFang YuanDecong SunXuejiao YangYanfang JuLijie WangHaitao TaoLuyuan TianChanghong ZhaoJunxun MaYi HuZhefeng LiuBackground: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC. Design: A single-center, single-arm, phase II study. Methods: Previously treated patients with locally advanced and metastatic NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutation genes had received at least one EGFR tyrosine kinase inhibitor and no more than two lines of chemotherapy regimen before the enrollment. The other patients had progressed on first-line chemotherapy with or without immunotherapy before the enrollment. The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by the investigator. Results: Our study encompassed 23 NSCLC patients between October 2019 and October 2022. For all patients, the confirmed ORR was 30.4%, and the disease control rate was 95.7%. The median progression-free survival (PFS) was 6.9 months (95% CI: 4.9 months–not reached). The median overall survival (OS) was not reached. 1- and 2-year OS rates were 85.6% (95% CI: 71.8%–100.0%) and 56.8% (95% CI: 37.7%–85.7%). Especially, for the 6 patients with EGFR genetic aberrations, the confirmed ORR was 33.3%, the median PFS was 10.3 months (95% CI: 1.8–18.8 months), and the median OS was 20.3 months (95% CI: 0.8–39.8 months). The most common grade 3 and above treatment-related adverse events were platelet count decreased, white blood cell count decreased, and hypertension. No unexpected adverse events were reported. Conclusion: Camrelizumab plus famitinib demonstrated encouraging clinical activity with a manageable safety profile in previously treated patients with locally advanced and metastatic NSCLC. The results warranted further validation. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR1900026641.https://doi.org/10.1177/17588359241311058 |
| spellingShingle | Ming Gao Xia Zhang Huan Yan Yan Zhao Fang Yuan Decong Sun Xuejiao Yang Yanfang Ju Lijie Wang Haitao Tao Luyuan Tian Changhong Zhao Junxun Ma Yi Hu Zhefeng Liu Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial Therapeutic Advances in Medical Oncology |
| title | Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial |
| title_full | Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial |
| title_fullStr | Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial |
| title_full_unstemmed | Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial |
| title_short | Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial |
| title_sort | efficacy and safety of camrelizumab plus famitinib in patients with previously treated non small cell lung cancer a single arm phase ii trial |
| url | https://doi.org/10.1177/17588359241311058 |
| work_keys_str_mv | AT minggao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT xiazhang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT huanyan efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT yanzhao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT fangyuan efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT decongsun efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT xuejiaoyang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT yanfangju efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT lijiewang efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT haitaotao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT luyuantian efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT changhongzhao efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT junxunma efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT yihu efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial AT zhefengliu efficacyandsafetyofcamrelizumabplusfamitinibinpatientswithpreviouslytreatednonsmallcelllungcancerasinglearmphaseiitrial |